Founded in 2010, Avistone Biotechnology is a private, global Oncology company, focused on targeted therapeutics. The company’s pipeline comprises of six assets, including: 1) Vebreltinib (PLB1001) (cMETi) which received conditional approval in China for MET Exon 14 Skipping NSCLC , 2) PLB1004 (EGFRi) for EGFR Exon 20 Insertion Mutations NSCLC, and 3) ANS014004 (ANS01), a next-generation Type II MET inhibitor, to be explored in NSCLC and other solid tumors. We are also exploring cMET/EGFR combinations with our clinical-stage Phase1b/2 development program investigating the combination of PLB1001 and PLB1004 in patients with metastatic NSCLC with MET amplification following EGFR-TKI failure in China. The company has over 200 employees globally with headquarters in Beijing, China. The company has raised $340 million in a Series A ($200M)and B ($140M) financing rounds. Investors include: Bain Capital, Vivo Capital, Primavera Capital, SDIC, IDG, Yanchaung Capital, and Cathay Capital.